Account
Inquiry
Tirzepatide 10mg is a revolutionary peptide compound that functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This innovative molecule has demonstrated significant potential in metabolic research applications, particularly for type 2 diabetes management and weight loss studies.
The molecular structure of tirzepatide 10mg features a unique modification with PEGylation on the lysine side chain, which enhances the peptide's water solubility and stability. This modification contributes to its extended half-life and improved pharmacokinetic profile compared to native GLP-1 analogs.
In clinical research settings, tirzepatide 10mg has shown remarkable efficacy. Studies indicate average weight reductions of 15-20.9% over 72 weeks, depending on dosage. The peptide's dual mechanism of action provides superior glucose control compared to selective GLP-1 receptor agonists alone.
Our tirzepatide 10mg is supplied as a white lyophilized powder with pharmaceutical-grade purity (99.9%). The product undergoes rigorous quality control testing including HPLC and MS analysis to ensure batch-to-batch consistency and optimal performance in research applications.
The peptide's sequence shares similarities with semaglutide but incorporates the distinctive PEG modification that enhances its therapeutic profile. Researchers have found that tirzepatide 10mg mimics natural GIP actions at the GIP receptor while maintaining potent GLP-1 receptor activity.
Current research focuses on tirzepatide's potential in treating obesity and overweight conditions with weight-related comorbidities. The peptide has received FDA Fast Track designation for these applications, highlighting its significant therapeutic promise.
For laboratory use only. This product is intended for research purposes by qualified professionals in controlled settings. Not for human consumption or diagnostic use.
